New guidelines cover VTE prophylaxis, diagnosis, anticoagulation, and HIT | ACP Hospitalist Weekly | ACP Hospitalist
Several guidelines related to venous thromboembolism (VTE) prevention and treatment were recently published by the American Society of Hematology, with more promised soon.
New class more likely to be used for reassurance than treatment, experts say.
ACP Hospitalist provides hospital-based physicians with news and information about the practice of hospital medicine.
PE recurrence same with vena cava filter plus anticoagulation as anticoagulation alone | ACP Hospitalist Weekly | ACP Hospitalist
Adding an inferior vena cava filter did not reduce the risk of recurrent pulmonary embolism (PE) compared to anticoagulation alone, according to a recent study of French patients hospitalized with PE.
Patient cases involving warfarin before cholecystectomy, atrial fibrillation and colonoscopy, and more.
ACC releases decision pathway for periop anticoagulation in nonvalvular afib | ACP Hospitalist Weekly | ACP Hospitalist
The pathway, based on expert consensus, offers recommendations on whether and how to periprocedurally bridge and the process of restarting anticoagulation after a procedure.
Restarting anticoagulation after GI bleed associated with reduced mortality in afib | ACP Hospitalist Weekly | ACP Hospitalist
Compared to patients who didn't restart medication, those who restarted oral anticoagulation alone had a significantly increased risk of major bleeding, but the risk of recurrent GI bleeding was not significantly increased.
Cases involving anticoagulants for afib after PCI, periprocedural anticoagulation, and others are presented.
Guidance released on use of new oral anticoagulants in nonvalvular afib | ACP Hospitalist Weekly | ACP Hospitalist
The European Heart Rhythm Association (EHRA) published guidance last week on using new oral anticoagulants in patients with nonvalvular atrial fibrillation (AF).
An alternative to plasma (Prothrombin Complex Concentrate, Human; brand name, Kcentra) was approved by the FDA last week for the urgent reversal of vitamin K antagonist (VKA) anticoagulation in adults with acute major bleeding.